Anti-VEGF therapy is primarily used to alleviate cerebral edema and radiation necrosis, yet it confers limited survival benefit, underscoring the spatiotemporal heterogeneity of the blood-tumor barrier and the persistence of non-classical vascularization pathways. This evidence concerns the gene VEGFA and neoplasm.